Pharmacokinetics of ampicillin/sulbactam in critically ill patients with acute kidney injury undergoing extended dialysis

Clinical Journal of the American Society of Nephrology

Volumn 7, Issue 3, 2012, Pages 385-390

  Lorenzen, Johan M ^a   Broll, Michael ^a   Kaever, Volkhard ^a   Burhenne, Heike ^a   Hafer, Carsten ^a   Clajus, Christian ^a   Knitsch, Wolfgang ^a   Burkhardt, Olaf ^a   Kielstein, Jan T ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

SULTAMICILLIN;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; ARTIFICIAL KIDNEY; BACTERIAL INFECTION; CLINICAL ARTICLE; CRITICALLY ILL PATIENT; DIALYSIS; FEMALE; HUMAN; INTENSIVE CARE UNIT; MALE;

ACUTE KIDNEY INJURY; ADULT; AGED; AGED, 80 AND OVER; AMPICILLIN; ANTI-BACTERIAL AGENTS; ANURIA; AREA UNDER CURVE; CRITICAL ILLNESS; DRUG ADMINISTRATION SCHEDULE; DRUG DOSAGE CALCULATIONS; DRUG MONITORING; EQUIPMENT DESIGN; FEMALE; GERMANY; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MEMBRANES, ARTIFICIAL; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, BIOLOGICAL; POLYMERS; PROSPECTIVE STUDIES; RENAL DIALYSIS; SULBACTAM; SULFONES; YOUNG ADULT;

EID: 84858062364     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.05690611     Document Type: Article

References (19)

1. Lode HM: Rational antibiotic therapy and the position of ampicillin/sulbactam. Int J Antimicrob Agents 32: 10-28, 2008
2. Polk RE, Fox C, Mahoney A, Letcavage J, MacDougall C: Measurement of adult antibacterial drug use in 130 US hospitals: Comparison of defined daily dose and days of therapy. Clin Infect Dis 44: 664-670, 2007
3. Blum RA, Kohli RK, Harrison NJ, Schentag JJ: Pharmacokinetics of ampicillin (2.0 grams) and sulbactam (1.0 gram) coadministered to subjects with normal and abnormal renal function and with end-stage renal disease on hemodialysis. Antimicrob Agents Chemother 33: 1470-1476, 1989
4. Fliser D, Kielstein JT: Technology insight: Treatment of renal failure in the intensive care unit with extended dialysis. Nat Clin Pract Nephrol 2: 32-39, 2006
5. Kumar VA, Yeun JY, Depner TA, Don BR: Extended daily dialysis vs. continuous hemodialysis for ICU patients with acute renal failure: A two-year single center report. Int J Artif Organs 27: 371-379, 2004
6. Marshall MR, Golper TA, Shaver MJ, Alam MG, Chatoth DK: Sustained low-efficiency dialysis for critically ill patients requiring renal replacement therapy. Kidney Int 60: 777-785, 2001
7. Marshall MR, Ma T, Galler D, Rankin AP, Williams AB: Sustained low-efficiency daily diafiltration (SLEDD-f) for critically ill patients requiring renal replacement therapy: Towards an adequate therapy. Nephrol Dial Transplant 19: 877-884, 2004
8. Burkhardt O, Hafer C, Langhoff A, Kaever V, Kumar V, Welte T, Haller H, Fliser D, Kielstein JT: Pharmacokinetics of ertapenem in critically ill patients with acute renal failure undergoing extended daily dialysis. Nephrol Dial Transplant 24: 267-271, 2009
9. Czock D, Hüsig-Linde C, Langhoff A, Schöpke T, Hafer C, de Groot K, Swoboda S, Kuse E, HallerH, Fliser D, Keller F, Kielstein JT: Pharmacokinetics of moxifloxacin and levofloxacin in intensive care unit patients who have acute renal failure and undergo extended daily dialysis. Clin J AmSocNephrol 1: 1263-1268, 2006
10. Fiaccadori E, Maggiore U, Rotelli C, Giacosa R, Parenti E, Picetti E, Sagripanti S, Manini P, Andreoli R, Cabassi A: Removal of linezolid by conventional intermittent hemodialysis, sustained low-efficiency dialysis, or continuous venovenous hemofiltration in patients with acute renal failure. Crit Care Med 32: 2437-2442, 2004
11. Kielstein JT, Czock D, Schöpke T, Hafer C, Bode-Böger SM, Kuse E, Keller F, Fliser D: Pharmacokinetics and total elimination of meropenem and vancomycin in intensive care unit patients undergoing extended daily dialysis. Crit Care Med 34: 51-56, 2006
12. Kielstein JT, Eugbers C, Bode-Boeger SM, Martens-Lobenhoffer J, Haller H, Joukhadar C, Traunmüller F, Knitsch W, Hafer C, Burkhardt O: Dosing of daptomycin in intensive care unit patients with acute kidney injury undergoing extended dialysis-a pharmacokinetic study. Nephrol Dial Transplant 25: 1537-1541, 2010
13. Swoboda S, Ober MC, Lichtenstern C, Saleh S, Schwenger V, Sonntag HG, Haefeli WE, Hempel G, Hoppe-Tichy T, Weigand MA: Pharmacokinetics of linezolid in septic patients with and without extended dialysis. Eur J Clin Pharmacol 66: 291-298, 2010
14. Bogard KN, Peterson NT, Plumb TJ, Erwin MW, Fuller PD, Olsen KM: Antibiotic dosing during sustained low-efficiency dialysis: Special considerations in adult critically ill patients. Crit Care Med 39: 560-570, 2011
15. Kielstein JT, Lorenzen J, Kaever V, Burhenne H, Broll M, Hafer C, Burkhardt O: Risk of underdosing of ampicillin/sulbactam in patients with acute kidney injury undergoing extended daily dialysis-a single case. Nephrol Dial Transplant 24: 2283-2285, 2009
16. Matzke GR, Aronoff GR, Atkinson AJ Jr, Bennett WM, Decker BS, Eckardt KU, Golper T, Grabe DW, Kasiske B, Keller F, Kielstein JT, Mehta R, Mueller BA, Pasko DA, Schaefer F, Sica DA, Inker LA, Umans JG, Murray P: Drug dosing consideration in patients with acute and chronic kidney disease-aclinical update fromKidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 80: 1122-1137, 2011
17. Kielstein JT, Kretschmer U, Ernst T, Hafer C, Bahr MJ, Haller H, Fliser D: Efficacy and cardiovascular tolerability of extended dialysis in critically ill patients: A randomized controlled study. Am J Kidney Dis 43: 342-349, 2004
18. Foulds G, Knirsch AK, Stankewich JP, Weidler DR: The parenteral kinetics of ampicillin/sulbactam in man. Int J Clin Pharmacol Res 5: 79-86, 1985
19. Betrosian AP, Frantzeskaki F, Xanthaki A, Georgiadis G: Highdose ampicillin-sulbactam as an alternative treatment of lateonset VAP from multidrug-resistant Acinetobacter baumannii. Scand J Infect Dis 39: 38-43, 2007